<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENYTEK- phenytoin sodiumÂ capsule, extended releaseÂ </strong><br>Clinical Solutions Wholesale<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bae34f60-49aa-4d28-a99c-8703f5d228af"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PHENYTEK<span class="Sup">Â®</span> (phenytoin sodium) is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-Diphenylhydantoin sodium salt, having a molecular weight of 274.25 and having the following structural formula and molecular formula:</p>
<div class="Figure">
<a name="id430"></a><img alt="ChemStruc" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc10b6de-3dbd-4f8a-8049-def272d0a2f1&amp;name=fc10b6de-3dbd-4f8a-8049-def272d0a2f1-01.jpg"><p class="MultiMediaCaption">C15H11N2NaO2 </p>
</div>
<p>Each PHENYTEK<span class="Sup">Â®</span> CAPSULE (extended phenytoin sodium capsule, USP) for oral administration contains 200 mg or 300 mg of phenytoin sodium, USP. Each capsule also contains the following inactive ingredients: colloidal silicon dioxide, hydroxyethyl cellulose, magnesium oxide, magnesium stearate, microcrystalline cellulose, povidone and sodium lauryl sulfate. In addition, each of the empty gelatin capsules contains the following: FD&amp;C Blue No. 1, gelatin, sodium lauryl sulfate and titanium dioxide. </p>
<p>The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze. </p>
<p>Product <span class="Italics">in vivo</span> performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to prompt phenytoin sodium capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1<span class="Sup">1</span>â?„<span class="Sub">2</span> to 3 hours.</p>
<p>PHENYTEK<span class="Sup">Â®</span> CAPSULES, 200 mg and 300 mg meet <span class="Italics">USP Dissolution Test 3</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_07c012a9-8953-43f7-b733-242c139d3d44"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_868703e1-30c1-41b6-9ae1-daa1ac8486a7"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Phenytoin is an antiepileptic drug which can be useful in the treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The primary site of action appears to be the <span class="Italics">motor cortex</span> where spread of <span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> </span>activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_279524d2-ea3a-44e4-bc7f-ebb2c8e52d7a"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics and Drug Metabolism</h2>
<p class="First">The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours. Steady-state therapeutic levels are achieved at least 7 to 10 days (5 to 7 half-lives) after initiation of therapy with recommended doses of 300 mg/day.</p>
<p>When serum level determinations are necessary, they should be obtained at least 5 to 7 half-lives after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen so that equilibrium or steady-state will have been achieved. Trough levels provide information about clinically effective serum level range and confirm patient compliance and are obtained just prior to the patientâ€™s next scheduled dose. Peak levels indicate an individualâ€™s threshold for emergence of dose related side effects and are obtained at the time of expected peak concentration. For extended phenytoin sodium capsules, peak serum levels occur 4 to 12 hours after administration.</p>
<p>Optimum control without clinical signs of toxicity occurs more often with serum levels between 10 and 20 mcg/mL, although some mild cases of tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> may be controlled with lower serum levels of phenytoin.</p>
<p>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem. Serum level determinations in such patients may be particularly helpful. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal.</p>
<p>Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but more importantly by tubular secretion. Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable at high plasma levels, small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these are in the upper range. The steady-state level may be disproportionately increased, with resultant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, from an increase in dosage of 10% or more.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08829a46-421e-4516-a395-3d7c37975418"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e6db688-e97c-4a22-ae81-e8c3faba6a54"></a><a name="section-2.3.1"></a><p></p>
<h3>Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h3>
<p class="First">Due to an increased fraction of unbound phenytoin in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, or in those with <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>, the interpretation of total phenytoin plasma concentrations should be made with caution (see <a href="#i4i_dosage_admin_id_4a4b0ccf-3a6a-4ba1-9fab-c0254e311f79">DOSAGE AND ADMINISTRATION</a>). Unbound phenytoin concentrations may be more useful in these patient populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6173e9ad-5726-49b2-b745-2c5b490e5bcc"></a><a name="section-2.3.2"></a><p></p>
<h3>Age</h3>
<p class="First">Phenytoin clearance tends to decrease with increasing age (20% less in patients over 70 years of age relative to that in patients 20 to 30 years of age). Phenytoin dosing requirements are highly variable and must be individualized (see <a href="#i4i_dosage_admin_id_4a4b0ccf-3a6a-4ba1-9fab-c0254e311f79">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_577013e6-1af7-4aad-80a0-a44e85446724"></a><a name="section-2.3.3"></a><p></p>
<h3>Gender and Race</h3>
<p class="First">Gender and race have no significant impact on phenytoin pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3ee28c3b-c18a-4503-8c6f-6368c6230a6c"></a><a name="section-2.3.4"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years and adolescents may require the minimum adult dose (300 mg/day).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_832c1ccd-09ea-491d-b02c-4c8c59d682e2"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PHENYTEK<span class="Sup">Â®</span> CAPSULES (extended phenytoin sodium capsules, USP) are indicated for the control of generalized tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) and complex partial (psychomotor, temporal lobe) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and prevention and treatment of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurring during or following neurosurgery.</p>
<p>Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see <a href="#i4i_dosage_admin_id_4a4b0ccf-3a6a-4ba1-9fab-c0254e311f79">DOSAGE AND ADMINISTRATION</a> and <a href="#i4i_clinical_pharmacology_id_07c012a9-8953-43f7-b733-242c139d3d44">CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_17fa598f-46fe-43c3-b4ff-2d95703b0822"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PHENYTEK<span class="Sup">Â®</span> CAPSULES (extended phenytoin sodium capsules) are contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to phenytoin, its inactive ingredients, or other hydantoins.</p>
<p>Coadministration of phenytoin is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6107106f-e43f-4b88-8fe4-d1479781fd21"></a><a name="section-5.1"></a><p></p>
<h2>Effects of Abrupt Withdrawal</h2>
<p class="First">Abrupt withdrawal of phenytoin in epileptic patients may precipitate <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, this should be done gradually. In the event of an allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, more rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd13af47-b78e-410d-8afc-16630ec9e390"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including phenytoin sodium, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p> Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p> The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p> The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.</p>
<p> Table 1 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="_RefID0EDGAE"></a><table>
<caption><span>Table 1 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</span></caption>
<col width="13%">
<col width="19%">
<col width="19%">
<col width="22%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"><p class="First">Indication</p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Placebo Patients<br>with Events<br>per 1,000 Patients</p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Drug Patients<br>with Events<br>per 1,000 Patients</p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Relative Risk:<br>Incidence of Events<br>in Drug<br>Patients/Incidence in<br>Placebo Patients</p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Risk Difference:<br>Additional Drug<br>Patients with<br>Events per 1,000<br>Patients</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></p></td>
<td valign="top"><p class="First">1</p></td>
<td valign="top"><p class="First">3.4</p></td>
<td valign="top"><p class="First">3.5</p></td>
<td valign="top"><p class="First">2.4</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Psychiatric</p></td>
<td valign="top"><p class="First">5.7</p></td>
<td valign="top"><p class="First">8.5</p></td>
<td valign="top"><p class="First">1.5</p></td>
<td valign="top"><p class="First">2.9</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Other</p></td>
<td valign="top"><p class="First">1</p></td>
<td valign="top"><p class="First">1.8</p></td>
<td valign="top"><p class="First">1.9</p></td>
<td valign="top"><p class="First">0.9</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Total</p></td>
<td class="Botrule" valign="top"><p class="First">2.4</p></td>
<td class="Botrule" valign="top"><p class="First">4.3</p></td>
<td class="Botrule" valign="top"><p class="First">1.8</p></td>
<td class="Botrule" valign="top"><p class="First">1.9</p></td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p> Anyone considering prescribing phenytoin sodium or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p> Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5daa1bbd-756c-4a0c-8ed5-9276f5fa428b"></a><a name="section-5.3"></a><p></p>
<h2>Serious Dermatologic Reactions</h2>
<p class="First">Serious and sometimes fatal dermatologic reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), have been reported with phenytoin treatment. The onset of symptoms is usually within 28 days, but can occur later. Phenytoin should be discontinued at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, unless the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. If a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs, the patient should be evaluated for signs and symptoms of Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (see DRESS/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> below). </p>
<p>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.  </p>
<p>The use of HLA-B*1502 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_09ff5c29-b4a9-4f52-a18c-e053918ae116"></a><a name="section-5.4"></a><p></p>
<h2>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS), also known as Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, has been reported in patients taking antiepileptic drugs, including phenytoin. Some of these events have been fatal or life threatening. DRESS typically, although not exclusively, presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, in association with other organ system involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, hematological abnormalities, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> sometimes resembling an acute <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, may be present even though <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1876f49f-df11-48bb-a0e5-d63610348f4b"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (see <a href="#i4i_contraindications_id_17fa598f-46fe-43c3-b4ff-2d95703b0822">CONTRAINDICATIONS</a>). Additionally, consider alternatives to structurally similar drugs such as carboxamides (e.g., carbamazepine), barbiturates, succinimides and oxazolidinediones (e.g., trimethadione) in these same patients. Similarly, if there is a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to these structurally similar drugs in the patient or immediate family members, consider alternatives to phenytoin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_33a20d1b-c589-4812-b6e7-8e715d864e9b"></a><a name="section-5.6"></a><p></p>
<h2>Hepatic Injury</h2>
<p class="First">Cases of acute hepatotoxicity, including infrequent cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute hepatic failure</span>, have been reported with phenytoin. These events may be part of the spectrum of DRESS or may occur in isolation. Other common manifestations include <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, elevated serum transaminase levels, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not readministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4f939212-81d7-4586-b6cd-c057855cf92b"></a><a name="section-5.7"></a><p></p>
<h2>Hematopoietic System</h2>
<p class="First">Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> with or without bone marrow suppression.</p>
<p>There have been a number of reports suggesting a relationship between phenytoin and the development of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> (local or generalized) including benign lymph node <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">pseudolymphoma</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and Hodgkinâ€™s Disease. Although a cause and effect relationship has not been established, the occurrence of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs of DRESS.</p>
<p>In all cases of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, follow-up observation for an extended period is indicated and every effort should be made to achieve <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control using alternative antiepileptic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_598147b4-ac91-4057-8824-b6f8f47f1433"></a><a name="section-5.8"></a><p></p>
<h2>Effects on Vitamin D and Bone</h2>
<p class="First">The chronic use of phenytoin in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> has been associated with decreased bone mineral density (<span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>) and bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. Phenytoin induces hepatic metabolizing enzymes. This may enhance the metabolism of vitamin D and decrease vitamin D levels, which may lead to <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>. Consideration should be given to screening with bone-related laboratory and radiological tests as appropriate and initiating treatment plans according to established guidelines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b22fab75-ddc9-487a-b2b9-9862f73bff49"></a><a name="section-5.9"></a><p></p>
<h2>Effects of Alcohol Use on Phenytoin Serum Levels</h2>
<p class="First">Acute alcoholic intake may increase phenytoin serum levels while chronic alcohol use may decrease serum levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5690de7b-35e0-424e-8ffb-bd3650881c67"></a><a name="section-5.10"></a><p></p>
<h2>Exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span></h2>
<p class="First">In view of isolated reports associating phenytoin with exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, caution should be exercised in using this medication in patients suffering from this disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_966baa3a-bf96-4f28-838f-ba582d0dbe14"></a><a name="section-5.11"></a><p></p>
<h2>Usage in Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d30d329d-7795-48da-932b-0c46d3433290"></a><a name="section-5.11.1"></a><p></p>
<h3>Clinical</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b60f6d2-4892-4e52-a1a0-275b898be506"></a><a name="section-5.11.1.1"></a><p></p>
<h4><span class="Bold">Risks to Mother</span></h4>
<p class="First">An increase in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of plasma phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage (see <a href="#i4i_section_id_ec38e7d5-6acf-4279-9eb6-66c908890bf3">PRECAUTIONS: Laboratory Tests</a>). However, postpartum restoration of the original dosage will probably be indicated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_48fcdf45-9976-4170-9c63-bd8174c3d598"></a><a name="section-5.11.1.2"></a><p></p>
<h4><span class="Bold">Risks to the Fetus</span></h4>
<p class="First">If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential harm to the fetus. </p>
<p> Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), minor anomalies (dysmorphic facial features, nail and digit hypoplasia), growth abnormalities (including <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>), and <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental deficiency</span> have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have also been several reported cases of malignancies, including <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, in children whose mothers received phenytoin during pregnancy. The overall incidence of malformations for children of epileptic women treated with antiepileptic drugs (phenytoin and/or others) during pregnancy is about 10%, or 2-to 3-fold that in the general population. However, the relative contributions of antiepileptic drugs and other factors associated with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> to this increased risk are uncertain and in most cases it has not been possible to attribute specific developmental abnormalities to particular antiepileptic drugs. </p>
<p> Patients should consult with their physicians to weigh the risks and benefits of phenytoin during pregnancy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c17ed874-a108-4c98-89b8-8e22598da58e"></a><a name="section-5.11.1.3"></a><p></p>
<h4><span class="Bold">Postpartum Period</span></h4>
<p class="First">A potentially life threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin <span class="Italics">in utero</span>. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08fc6559-43e5-4088-a604-24e145197608"></a><a name="section-5.11.2"></a><p></p>
<h3>Preclinical</h3>
<p class="First">Increased resorption and malformation rates have been reported following administration of phenytoin doses of 75 mg/kg or higher (approximately 120% of the maximum human loading dose or higher on a mg/m<span class="Sup">2</span> basis) to pregnant rabbits.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8ae83acf-2574-4721-9de9-31da291b4d8e"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_8dad87dc-6900-45a9-a19a-644535aac7d3"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">The liver is the chief site of biotransformation of phenytoin; patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>, elderly patients, or those who are gravely ill may show early signs of toxicity.</p>
<p>A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined. If early signs of dose related CNS toxicity develop, plasma levels should be checked immediately.</p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, resulting from the drugâ€™s inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.</p>
<p>Phenytoin is not indicated for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> due to hypoglycemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated.</p>
<p>Phenytoin is not effective for absence (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. If tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) and absence (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are present, combined drug therapy is needed.</p>
<p>Serum levels of phenytoin sustained above the optimal range may produce <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional states</span> referred to as â€œdelirium,â€? â€œpsychosis,â€? or â€œencephalopathy,â€? or rarely irreversible cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, plasma levels are recommended. Dose reduction of phenytoin therapy is indicated if plasma levels are excessive; if symptoms persist, termination is recommended (see <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_525327c9-2c52-43c4-a662-3e78c4ac60a4"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking phenytoin. Instruct patients to take phenytoin only as prescribed.  </p>
<p>Patients taking phenytoin should be advised of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, e.g., surgery, etc.  </p>
<p>Patients should be made aware of the early toxic signs and symptoms of potential hematologic, dermatologic, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or hepatic reactions. These symptoms may include, but are not limited to, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the mouth, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and petechial or purpuric <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and in the case of liver reactions, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. The patient should be advised that, because these signs and symptoms may signal a serious reaction, that they must report any occurrence immediately to a physician. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use.    </p>
<p>Patients should also be cautioned on the use of other drugs or alcoholic beverages without first seeking the physicianâ€™s advice.  </p>
<p>The importance of good dental hygiene should be stressed in order to minimize the development of gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and its complications.  </p>
<p>Patients, their caregivers and families should be counseled that AEDs, including phenytoin sodium, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.  </p>
<p>Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This Registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see <a href="#i4i_section_id_10511c7a-eb93-47f1-bdf7-be6b2d9ce5a8">PRECAUTIONS: Pregnancy</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec38e7d5-6acf-4279-9eb6-66c908890bf3"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Phenytoin serum level determinations may be necessary to achieve optimal dosage adjustments. Phenytoin doses are usually selected to attain therapeutic plasma total phenytoin concentrations of 10 to 20 mcg/mL(unbound phenytoin concentrations of 1 to 2 mcg/mL).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7c4aa13-ee38-469e-b1ee-d06bf0b85c93"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement. Phenytoin is metabolized by hepatic cytochrome P450 enzymes CYP2C9 and CYP2C19, and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.  Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected.</p>
<p>The most commonly occurring drug interactions are listed below.</p>
<p>Note: The list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f52e5342-b4b7-48ba-9e1c-f702621119aa"></a><a name="section-6.4.1"></a><p></p>
<h3>Drugs that Affect Phenytoin Concentrations</h3>
<dl>
<dt>â€¢</dt>
<dd>Drugs, which may increase phenytoin serum levels, include: acute alcohol intake, amiodarone, anti-epileptic agents (felbamate, topiramate, oxcarbazepine), azoles (fluconazole, ketoconazole, itraconazole, voriconazole), chloramphenicol, chlordiazepoxide, cimetidine, diazepam, disulfiram, estrogens, ethosuximide, fluorouracil, fluoxetine, fluvoxamine, H2-antagonists, halothane, isoniazid, methylphenidate, omeprazole, phenothiazines, salicylates, sertraline, succinimides, sulfonamides, ticlopidine, tolbutamide, trazodone and warfarin.</dd>
<dt>â€¢</dt>
<dd>Drugs, which may decrease phenytoin levels include: carbamazepine, chronic <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>, nelvinavir, reserpine, ritonavir and sucralfate. </dd>
<dt>â€¢</dt>
<dd>Ingestion times of phenytoin and antacid preparations containing calcium should be staggered in patients with low serum phenytoin levels to prevent absorption problems.</dd>
<dt>â€¢</dt>
<dd>Drugs, which may either increase or decrease phenytoin serum levels, include: phenobarbital, sodium valproate and valproic acid. Similarly, the effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable.</dd>
<dt>â€¢</dt>
<dd>The addition or withdrawal of these agents in patients on phenytoin therapy may require an adjustment of the phenytoin dose to achieve optimal clinical outcome.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08766947-6241-4745-8540-03f8f6dee28e"></a><a name="section-6.4.2"></a><p></p>
<h3>Drugs Affected by Phenytoin</h3>
<dl>
<dt>â€¢</dt>
<dd>Drugs that should not be coadministered with phenytoin: delavirdine</dd>
<dt>â€¢</dt>
<dd>Drugs whose efficacy is impaired by phenytoin include: azoles (fluconazole, ketoconazole, itraconazole, voriconazole), corticosteroids, doxycycline, estrogens, furosemide, irinotecan, oral contraceptives, paclitaxel, paroxetine, quinidine, rifampin, sertraline, teniposide, theophylline, vitamin D, and warfarin.</dd>
<dt>â€¢</dt>
<dd>Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin.</dd>
<dt>â€¢</dt>
<dd>Phenytoin decreases plasma concentrations of certain HIV antivirals (amprenavir, efavirenz, Kaletra<span class="Sup">â€ </span> (lopinavir/ritonavir), indinavir, nelfinavir, ritonavir, saquinavir) and anti-epileptic agents (felbamate, topiramate, oxcarbazepine, quetiapine).  </dd>
<dt>â€¢</dt>
<dd>The addition or withdrawal of phenytoin during concomitant therapy with these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_47a7dad9-a2ad-4e92-80bd-22762aa240a1"></a><a name="section-6.5"></a><p></p>
<h2>Drug Enteral Feeding/Nutritional Preparations Interaction</h2>
<p class="First">Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin plasma levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67b42658-31ba-4762-98cb-8f24fced9d62"></a><a name="section-6.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Phenytoin may decrease serum concentrations of T<span class="Sub">4</span>. It may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may cause increased serum levels of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).</p>
<p> Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56317d73-4d22-47c0-8269-7a3b2c7a32aa"></a><a name="section-6.7"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">See <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a> section for information on carcinogenesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10511c7a-eb93-47f1-bdf7-be6b2d9ce5a8"></a><a name="section-6.8"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1105f7a9-60c7-4208-9482-32388eeb9981"></a><a name="section-6.8.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<p class="First">See <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a>.</p>
<p>To provide information regarding the effects of <span class="Italics">in utero </span>exposure to phenytoin sodium, physicians are advised to recommend that pregnant patients taking phenytoin sodium enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6d2da48-67b3-49c5-baa5-60df234b4c77"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Infant breast feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_42a8f2c7-6b7c-414b-9a22-39f0ceb4be1f"></a><a name="section-6.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <a href="#i4i_dosage_admin_id_4a4b0ccf-3a6a-4ba1-9fab-c0254e311f79">DOSAGE AND ADMINISTRATION</a>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_f54ce4c6-c7cc-4e1c-bdfd-b755e05529bf"></a><a name="section-6.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Phenytoin clearance tends to decrease with increasing age (see <a href="#ID_08829a46-421e-4516-a395-3d7c37975418">CLINICAL PHARMACOLOGY: Special Populations</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a1743da8-d42e-468e-854e-04a05371abb1"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> in the form of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and rarely more serious forms (see Skin and Appendages paragraph below) and DRESS (see <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a>) have been observed. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has also been reported.  </p>
<p>There have also been reports of coarsening of facial features, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and immunoglobulin abnormalities.</p>
<p><span class="Bold">Nervous System:</span> The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, decreased coordination, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, transient <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, motor <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitchings</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> have also been observed. There have also been rare reports of phenytoin induced <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>, including <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, similar to those induced by phenothiazine and other neuroleptic drugs.</p>
<p>A predominantly sensory peripheral <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> has been observed in patients receiving long-term phenytoin therapy.</p>
<p><span class="Bold">Digestive System: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, enlargement of the lips, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, toxic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
<p><span class="Bold">Skin and Appendages: </span>Dermatological manifestations sometimes accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> have included scarlatiniform or <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform rashes</span>. A <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform rash</span> (<span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>-like) is the most common; other types of <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (see <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a>). There have also been reports of <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>.</p>
<p><span class="Bold">Hematologic and Lymphatic System: </span>Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> with or without bone marrow suppression. While <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span> and <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> have occurred, these conditions usually respond to folic acid therapy. <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> including benign lymph node <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">pseudolymphoma</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and Hodgkinâ€™s Disease have been reported (see <a href="#i4i_warnings_id_a409b861-20c3-4199-a878-2d5e5ca08f19">WARNINGS</a>).</p>
<p><span class="Bold">Special Senses: </span>Altered taste sensation including metallic taste.</p>
<p><span class="Bold">Urogenital:</span>Peyronieâ€™s disease.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d78f4a74-7891-4216-b33e-64835487c700"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The lethal dose in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>. Other signs are <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The patient may become <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> and hypotensive. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is due to respiratory and circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>There are marked variations among individuals with respect to phenytoin plasma levels where toxicity may occur. <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>, on lateral gaze, usually appears at 20 mcg/mL, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> at 30 mcg/mL, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> appear when the plasma concentration is over 40 mcg/mL, but as high a concentration as 50 mcg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration over 100 mcg/mL with complete recovery.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37e20699-f9c5-4171-b014-c3d347dcfe57"></a><a name="section-8.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment is nonspecific since there is no known antidote.</p>
<p>The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> in pediatric patients.</p>
<p>In acute overdosage, the possibility of other CNS depressants, including alcohol, should be borne in mind.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4a4b0ccf-3a6a-4ba1-9fab-c0254e311f79"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Serum concentrations should be monitored in changing from extended phenytoin sodium capsules, USP, to prompt phenytoin sodium capsules, USP, and from the sodium salt to the free acid form.</p>
<p>PHENYTEK<span class="Sup">Â®</span> CAPSULES (extended phenytoin sodium capsules, USP) are formulated with the sodium salt of phenytoin. Because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3daa947-9799-4e32-b6a1-d0fe0bcbac3d"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments - the clinically effective serum level is usually 10 to 20 mcg/mL. With recommended dosage, a period ofÂ 7 toÂ 10 days may be required to achieve steady-state blood levels with phenytoin and changes in dosage (increase or decrease) should not be carried out at intervals shorter thanÂ 7 toÂ 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c67ff07f-4dfa-4cf5-8595-17439dbe2d90"></a><a name="section-9.2"></a><p></p>
<h2>Adult Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5718a693-f978-401a-8011-1e7725cefb26"></a><a name="section-9.2.1"></a><p></p>
<h3>Divided Daily Dosage</h3>
<p class="First">Patients who have received no previous treatment may be started on one 100 mg extended phenytoin sodium capsule three times daily and the dosage then adjusted to suit individual requirements. For most adults, the satisfactory maintenance dosage will be one 100 mg capsule three to four times a day. An increase up to one 200 mg PHENYTEK<span class="Sup">Â®</span> three times a day may be made, if necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dddaaf4a-a113-4b47-8c8c-b93f5540144e"></a><a name="section-9.2.2"></a><p></p>
<h3>Once-A-Day Dosage</h3>
<p class="First">In adults, if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control is established with divided doses of three 100 mg extended phenytoin sodium capsules daily, once-a-day dosage with 300 mg PHENYTEK<span class="Sup">Â®</span> may be considered. Studies comparing divided doses of 300 mg with a single daily dose of this quantity indicated absorption, peak plasma levels, biologic half-life, difference between peak and minimum values, and urinary recovery were equivalent. Once-a-day dosage offers a convenience to the individual patient or to nursing personnel for institutionalized patients and is intended to be used only for patients requiring this amount of drug daily. A major problem in motivating noncompliant patients may also be lessened when the patient can take this drug once a day. However, patients should be cautioned not to miss a dose, inadvertently.</p>
<p>Only extended phenytoin sodium capsules are recommended for once-a-day dosing. Inherent differences in dissolution characteristics and resultant absorption rates of phenytoin due to different manufacturing procedures and/or dosage forms preclude such recommendation for other phenytoin products. When a change in the dosage form or brand is prescribed, careful monitoring of phenytoin serum levels should be carried out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a03be461-1979-4b87-85d6-3071f37bb6eb"></a><a name="section-9.2.3"></a><p></p>
<h3>Loading Dose</h3>
<p class="First">Some authorities have advocated use of an oral loading dose of phenytoin in adults who require rapid steady-state serum levels and where intravenous administration is not desirable. This dosing regimen should be reserved for patients in a clinic or hospital setting where phenytoin serum levels can be closely monitored. Patients with a history of renal or liver disease should not receive the oral loading regimen.</p>
<p>Initially, one gram of extended phenytoin sodium capsules is divided intoÂ three doses (400 mg, 300 mg, 300 mg) and administered at 2 hour intervals. Normal maintenance dosage is then instituted 24 hours after the loading dose, with frequent serum level determinations.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7f2c5e3a-aff3-4a01-8a1e-6c8aed7c842c"></a><a name="section-9.3"></a><p></p>
<h2>Dosing in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a1c01447-bef4-469f-8140-63eedfa28482"></a><a name="section-9.3.1"></a><p></p>
<h3>Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h3>
<p class="First">Due to an increased fraction of unbound phenytoin in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, or in those with <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>, the interpretation of total phenytoin plasma concentrations should be made with caution. Unbound phenytoin concentrations may be more useful in these patient populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2aff7fc-83d7-400c-a2b1-c7bc5cb5b0fc"></a><a name="section-9.3.2"></a><p></p>
<h3>Elderly Patients</h3>
<p class="First">Phenytoin clearance is decreased slightly in elderly patients and lower or less frequent dosing may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2b7ccac0-6875-4470-82c6-da93bc1097c3"></a><a name="section-9.3.3"></a><p></p>
<h3>Pediatric</h3>
<p class="First">Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old and adolescents may require the minimum adult dose (300 mg/day).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a09ae41f-ee33-4551-9fed-2a5ef67b3bd1"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PHENYTEK<span class="Sup">Â®</span> CAPSULES (extended phenytoin sodium capsules, USP) are available containing 200 mg or 300 mg of phenytoin sodium, USP.</p>
<p>The 200 mg capsule has a dark blue opaque cap and a blue opaque body. The hard-shell gelatin capsule is filled with two white to off-white round tablets. The capsule is rectified radial printed with <span class="Bold">BERTEK</span> over <span class="Bold">670 </span>in black ink on both the cap and the body. They are available as follows:</p>
<p>NDC 0378-2670-93<br>bottles of 30 capsules</p>
<p>NDC 0378-2670-01<br>bottles of 100 capsules</p>
<p>The 300 mg capsule has a blue opaque cap and a blue opaque body. The hard-shell gelatin capsule is filled with three white to off-white round tablets. The capsule is rectified radial printed with <span class="Bold">BERTEK</span> over <span class="Bold">750 </span>in black ink on both the cap and the body. They are available as follows:</p>
<p>NDC 0378-3750-93<br>bottles of 30 capsules</p>
<p>NDC 0378-3750-01<br>bottles of 100 capsules</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light and moisture.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST: </span>Dispense a Medication Guide with each prescription.</p>
<p>U.S. Patent No. 6,274,168</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_d2788749-31e4-4b6f-974d-e4a6b440d412"></a><a name="section-11"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">PHENYTEK<span class="Sup">Â®</span> CAPSULES</span></p>
<p><span class="Bold">(extended phenytoin sodium capsules, USP)</span></p>
<p>Read this Medication Guide before you start taking PHENYTEK<span class="Sup">Â®</span> CAPSULES and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about PHENYTEK<span class="Sup">Â®</span> CAPSULES, ask your healthcare provider or pharmacist. </p>
<p><span class="Bold">What is the most important information I should know about PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<p><span class="Bold">Do not stop taking PHENYTEK<span class="Sup">Â®</span> CAPSULES without first talking to your healthcare provider. </span>Stopping PHENYTEK<span class="Sup">Â®</span> CAPSULES suddenly can cause serious problems. </p>
<p><span class="Bold">PHENYTEK<span class="Sup">Â®</span> CAPSULES can cause serious side effects including: </span></p>
<p><span class="Bold">1. Like other antiepileptic drugs, PHENYTEK<span class="Sup">Â®</span> CAPSULES may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. </span></p>
<p><span class="Bold">Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: </span></p>
<dl>
<dt>â€¢</dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </dd>
<dt>â€¢</dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </dd>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </dd>
<dt>â€¢</dt>
<dd>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> </dd>
<dt>â€¢</dt>
<dd>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </dd>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </dd>
<dt>â€¢</dt>
<dd>acting aggressive, being angry or violent </dd>
<dt>â€¢</dt>
<dd>acting on dangerous impulses </dd>
<dt>â€¢</dt>
<dd>an extreme increase activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) </dd>
<dt>â€¢</dt>
<dd>other unusual changes in behavior or mood </dd>
</dl>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. </dd>
<dt>â€¢</dt>
<dd>Keep all follow-up visits with your healthcare provider as scheduled. </dd>
</dl>
<p>Call your healthcare provider between visits as needed, especially if you are worried about symptoms. </p>
<p><span class="Bold">Do not stop taking PHENYTEK<span class="Sup">Â®</span> CAPSULES without first talking to a healthcare provider. </span>Stopping PHENYTEK<span class="Sup">Â®</span> CAPSULES suddenly can cause serious problems. Stopping a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine suddenly in a patient who has <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>). </p>
<p>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. </p>
<p><span class="Bold">2. PHENYTEK<span class="Sup">Â®</span> CAPSULES may harm your unborn baby. </span></p>
<dl>
<dt>â€¢</dt>
<dd>If you take PHENYTEK<span class="Sup">Â®</span> CAPSULES during pregnancy, your baby is at risk for serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> may occur even in children born to women who are not taking any medicines and do not have other risk factors </dd>
<dt>â€¢</dt>
<dd>If you take PHENYTEK<span class="Sup">Â®</span> CAPSULES during pregnancy, your baby is also at risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems right after birth. Your healthcare provider may give you and your baby medicine to prevent this. </dd>
<dt>â€¢</dt>
<dd>All women of childbearing age should talk to their healthcare provider about using other possible treatments instead of PHENYTEK<span class="Sup">Â®</span> CAPSULES. If the decision is made to use PHENYTEK<span class="Sup">Â®</span> CAPSULES, you should use effective birth control (contraception) unless you are planning to become pregnant. </dd>
<dt>â€¢</dt>
<dd>Tell your healthcare provider right away if you become pregnant while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES. You and your healthcare provider should decide if you will take PHENYTEK<span class="Sup">Â®</span> CAPSULES while you are pregnant. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Pregnancy Registry</span>: If you become pregnant while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. </dd>
</dl>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Swollen glands</span> (lymph nodes) </span></p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> or serious problems which may affect organs and other parts of your body like the liver or blood cells.</span> You may or may not have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with these types of reactions. Symptoms can include any of the following:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips or tongue </dd>
<dt>â€¢</dt>
<dd>trouble swallowing or breathing </dd>
<dt>â€¢</dt>
<dd>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span> (lymph nodes) or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> that do not go away or come and go </dd>
<dt>â€¢</dt>
<dd>painful sores in the mouth or around your eyes </dd>
<dt>â€¢</dt>
<dd>yellowing of your skin or eyes </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </dd>
<dt>â€¢</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> </dd>
<dt>â€¢</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> </dd>
<dt>â€¢</dt>
<dd>frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that does not go away</dd>
<dt>â€¢</dt>
<dd>loss of appetite (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away if you have any of the symptoms listed above. </span></p>
<p><span class="Bold">What are PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<p>PHENYTEK<span class="Sup">Â®</span> CAPSULES are a prescription medicine used to treat tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>), complex partial (psychomotor or temporal lobe) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and to prevent and treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that happen during or after brain surgery. </p>
<p><span class="Bold">Who should not take PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<p>Do not take PHENYTEK<span class="Sup">Â®</span> CAPSULES if you: </p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to phenytoin or any of the ingredients in PHENYTEK<span class="Sup">Â®</span> CAPSULES. See the end of this leaflet for a complete list of ingredients in PHENYTEK<span class="Sup">Â®</span> CAPSULES. </dd>
<dt>â€¢</dt>
<dd>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to CEREBYX<span class="Sup">â€ </span> (fosphenytoin), PEGANONE<span class="Sup">â€ </span> (ethotoin), or MESANTOIN<span class="Sup">â€ </span> (mephenytoin). </dd>
<dt>â€¢</dt>
<dd>take delavirdine </dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<p>Before you take PHENYTEK<span class="Sup">Â®</span> CAPSULES, tell your healthcare provider if you: </p>
<dl>
<dt>â€¢</dt>
<dd>Have or had liver disease </dd>
<dt>â€¢</dt>
<dd>Have or had <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> </dd>
<dt>â€¢</dt>
<dd>Have or had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </dd>
<dt>â€¢</dt>
<dd>Have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior </dd>
<dt>â€¢</dt>
<dd>Are pregnant or plan to become pregnant. If you become pregnant while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES, the level of phenytoin in your blood may decrease, causing your <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> to become worse. Your healthcare provider may change your dose of PHENYTEK<span class="Sup">Â®</span> CAPSULES. </dd>
<dt>â€¢</dt>
<dd>Are breast-feeding or plan to breast-feed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take PHENYTEK<span class="Sup">Â®</span> CAPSULES or breast-feed. You should not do both. </dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p>Taking PHENYTEK<span class="Sup">Â®</span> CAPSULES with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. </p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Take PHENYTEK<span class="Sup">Â®</span> CAPSULES exactly as prescribed. Your healthcare provider will tell you how much PHENYTEK<span class="Sup">Â®</span> CAPSULES to take. </dd>
<dt>â€¢</dt>
<dd>Your healthcare provider may change your dose. Do not change your dose of PHENYTEK<span class="Sup">Â®</span> CAPSULES without talking to your healthcare provider. </dd>
<dt>â€¢</dt>
<dd>PHENYTEK<span class="Sup">Â®</span> CAPSULES can cause overgrowth of your gums. Brushing and flossing your teeth and seeing a dentist regularly while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES can help prevent this. </dd>
<dt>â€¢</dt>
<dd>If you take too much PHENYTEK<span class="Sup">Â®</span> CAPSULES, call your healthcare provider or local Poison Control Center right away. </dd>
<dt>â€¢</dt>
<dd>Do not stop taking PHENYTEK<span class="Sup">Â®</span> CAPSULES without first talking to your healthcare provider. Stopping PHENYTEK<span class="Sup">Â®</span> CAPSULES suddenly can cause serious problems. </dd>
</dl>
<p><span class="Bold">What should I avoid while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not drink alcohol while you take PHENYTEK<span class="Sup">Â®</span> CAPSULES without first talking to your healthcare provider. Drinking alcohol while taking PHENYTEK<span class="Sup">Â®</span> CAPSULES may change your blood levels of phenytoin which can cause serious problems. </dd>
<dt>â€¢</dt>
<dd>Do not drive, operate heavy machinery or do other dangerous activities until you know how PHENYTEK<span class="Sup">Â®</span> CAPSULES affect you. PHENYTEK<span class="Sup">Â®</span> CAPSULES can slow your thinking and motor skills. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<p>See â€œWhat is the most important information I should know about PHENYTEK<span class="Sup">Â®</span> CAPSULES?â€? </p>
<p><span class="Bold">PHENYTEK<span class="Sup">Â®</span> CAPSULES may cause other serious side effects including: </span></p>
<dl>
<dt>â€¢</dt>
<dd>Softening of your bones (<span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>). This can cause broken bones. </dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away, if you have any of the symptoms listed above. </span></p>
<p>The most common side effects of PHENYTEK<span class="Sup">Â®</span> CAPSULES include: </p>
<dl>
<dt>â€¢</dt>
<dd>problems with walking and coordination </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </dd>
<dt>â€¢</dt>
<dd>trouble sleeping </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </dd>
</dl>
<p>These are not all the possible side effects of PHENYTEK<span class="Sup">Â®</span> CAPSULES. For more information, ask your healthcare provider or pharmacist. </p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold">How should I store PHENYTEK<span class="Sup">Â®</span> CAPSULES? </span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Store PHENYTEK<span class="Sup">Â®</span> CAPSULES at room temperature between 20Â° to 25Â°C (68Â° to 77Â°F) in tight, light-resistant containers. </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Protect from light and moisture.</span></dd>
</dl>
<p><span class="Bold">Keep PHENYTEK<span class="Sup">Â®</span> CAPSULES and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about PHENYTEK<span class="Sup">Â®</span> CAPSULES</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PHENYTEK<span class="Sup">Â®</span> CAPSULES for a condition for which it was not prescribed. Do not give PHENYTEK<span class="Sup">Â®</span> CAPSULES to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Medication Guide summarizes the most important information about PHENYTEK<span class="Sup">Â®</span> CAPSULES. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about PHENYTEK<span class="Sup">Â®</span> CAPSULES that was written for healthcare professionals. </p>
<p>For more information about PHENYTEK<span class="Sup">Â®</span> CAPSULES, visit Mylan.com or call Mylan Pharmaceuticals Inc. toll free at 1-877-446-3679 (1-877-4-INFO-RX). </p>
<p><span class="Bold">What are the ingredients in PHENYTEK<span class="Sup">Â®</span> CAPSULES (extended phenytoin sodium capsules, USP)? </span></p>
<p>The 200 mg capsule has a dark blue opaque cap and a blue opaque body. The hard-shell gelatin capsule is filled with two white to off-white round tablets. The capsule is rectified radial printed with <span class="Bold">BERTEK</span> over <span class="Bold">670 </span>in black ink on both the cap and the body. </p>
<p>The 300 mg capsule has a blue opaque cap and a blue opaque body. The hard-shell gelatin capsule is filled with three white to off-white round tablets. The capsule is rectified radial printed with <span class="Bold">BERTEK</span> over <span class="Bold">750 </span>in black ink on both the cap and the body. </p>
<p><span class="Bold">Active ingredient:</span> phenytoin sodium, USP </p>
<p><span class="Bold">Inactive ingredients:</span> colloidal silicon dioxide, hydroxyethyl cellulose, magnesium oxide, magnesium stearate, microcrystalline cellulose, povidone and sodium lauryl sulfate. In addition, each of the empty gelatin capsules contains the following: D&amp;C Red No. 28, D&amp;C Red No. 33, FD&amp;C Blue No. 1, gelatin, sodium lauryl sulfate and titanium dioxide. The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
<p><span class="Sup">â€  </span>The brands listed are trademarks of their respective owners.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>REVISED JULY 2013<br>BKPHTK:R12m/MG: BKPHTK:R3</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ca4751f1-dc62-4de0-8f54-9f59a123ae25"></a><a name="section-12"></a><p></p>
<h1>Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg</span></p>
<p><span class="Bold">NDC 0378-2670-93</span></p>
<p><span class="Bold">PHENYTEK<span class="Sup">Â®</span></span><br><span class="Bold">(extended phenytoin</span><br><span class="Bold">sodium capsules, USP)</span></p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the</span><br><span class="Bold">accompanying Medication</span><br><span class="Bold">Guide to each patient.</span></p>
<p><span class="Bold">Rx only 30 CAPSULES</span></p>
<p>Each capsule contains:<br>Phenytoin<br>sodium, USP 200 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication </span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light and moisture.</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505Â U.S.A.</p>
<p><span class="Bold">www.mylan.com</span></p>
<p>U.S. Patent No. 6,274,168</p>
<p><span class="Bold">RBK2670H3</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e8691930-a6f3-489c-bd18-d94023e64d96"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 300 mg</span></p>
<p><span class="Bold">PHENYTEK<span class="Sup">Â®</span></span><br><span class="Bold">(extended phenytoin</span><br><span class="Bold">sodium capsules, USP)</span></p>
<p><span class="Bold">300 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the</span><br><span class="Bold">accompanying Medication</span><br><span class="Bold">Guide to each patient.</span></p>
<p><span class="Bold">Rx only 30 CAPSULES</span></p>
<p>Each capsule contains:<br>Phenytoin<br>sodium, USP 300 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication </span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light and moisture.</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<div class="Figure">
<a name="id1236"></a><img alt="300mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc10b6de-3dbd-4f8a-8049-def272d0a2f1&amp;name=fc10b6de-3dbd-4f8a-8049-def272d0a2f1-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENYTEKÂ 		
					</strong><br><span class="contentTableReg">phenytoin sodium capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58118-3750(NDC:0378-3750)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENYTOIN SODIUM</strong> (PHENYTOIN) </td>
<td class="formItem">PHENYTOIN SODIUM</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue opaque) ,Â BLUE (blue opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BERTEK;750</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58118-3750-3</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:58118-3750-6</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:58118-3750-9</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:58118-3750-8</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:58118-3750-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040298</td>
<td class="formItem">12/10/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Clinical Solutions Wholesale
							(078710347)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Clinical Solutions Wholesale (078710347)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Clinical Solutions Wholesale</td>
<td class="formItem"></td>
<td class="formItem">078710347</td>
<td class="formItem">REPACK(58118-3750), RELABEL(58118-3750)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fc10b6de-3dbd-4f8a-8049-def272d0a2f1</div>
<div>Set id: fc10b6de-3dbd-4f8a-8049-def272d0a2f1</div>
<div>Version: 1</div>
<div>Effective Time: 20140701</div>
</div>
</div>Â <div class="DistributorName">Clinical Solutions Wholesale</div></p>
</body></html>
